Grenda Anna, Galant Natalia, Łomża-Łaba Aleksandra, Krawczyk Paweł, Jankowski Tomasz, Chmielewska Izabela, Szczyrek Michał, Kieszko Robert, Milanowski Janusz
Department of Pneumonology, Oncology and Allergology, Medical University of Lublin, Jaczewskiego 8, 20-954 Lublin, Poland.
Int J Mol Sci. 2025 Jun 25;26(13):6095. doi: 10.3390/ijms26136095.
The possibilities of small-cell lung cancer (SCLC) therapy were strictly limited for years, leading to high patient mortality rates. New approaches to SCLC treatment are being proposed, including chemoimmunotherapy. However, biomarkers enabling appropriate personalization of therapy in SCLC patients have not been identified yet. Even though molecular subtyping (, , , and ) seems pivotal in the management of SCLC, expression of other genes might be potentially valuable during patients' stratification. Due to their crucial role in tumorigenesis and SCLC invasiveness, benefits arising from and gene evaluation are suggested. Our study was designed to evaluate the relationship between the mRNA expression of these genes and chemoimmunotherapy efficacy in SCLC patients. A total of 35 patients with extensive-stage SCLC (ES-SCLC) treated with first-line chemoimmunotherapy were involved in the study. mRNA expression of and genes was evaluated using the RT-qPCR technique in FFPE tissue collected from all patients. Molecular results were correlated with clinicopathological features and outcome of disease (OS, PFS). We detected expression in 60% (21 of 35) of the samples. expression was higher in patients with longer PFS ( = 0.05) and with the T4 feature in the TNM scale ( = 0.08). mRNA was expressed in all FFPE tissues. We observed that risk of progression and death was higher in patients with higher expression of mRNA ( = 0.06 and = 0.04, respectively). Our study showed that and expression might serve as additional biomarkers for prediction of chemoimmunotherapy efficacy in ES-SCLC patients.
多年来，小细胞肺癌（SCLC）的治疗方案极为有限，导致患者死亡率居高不下。目前正在提出SCLC治疗的新方法，包括化学免疫疗法。然而，尚未确定能够实现SCLC患者治疗适当个体化的生物标志物。尽管分子亚型（、、和）在SCLC的管理中似乎至关重要，但在患者分层过程中，其他基因的表达可能具有潜在价值。鉴于它们在肿瘤发生和SCLC侵袭性中的关键作用，有人提出评估和基因会带来益处。我们的研究旨在评估这些基因的mRNA表达与SCLC患者化学免疫治疗疗效之间的关系。共有35例接受一线化学免疫治疗的广泛期SCLC（ES-SCLC）患者参与了该研究。使用RT-qPCR技术在从所有患者收集的FFPE组织中评估和基因的mRNA表达。分子结果与临床病理特征和疾病结局（总生存期、无进展生存期）相关。我们在60%（35例中的21例）的样本中检测到表达。在无进展生存期较长的患者（=0.05）和TNM分期为T4特征的患者中（=0.08），表达较高。所有FFPE组织中均表达了mRNA。我们观察到，mRNA表达较高的患者进展和死亡风险更高（分别为=0.06和=0.04）。我们的研究表明，和表达可能作为预测ES-SCLC患者化学免疫治疗疗效的额外生物标志物。
